Cinaciguat

Names

[ Name ]:
Cinaciguat

[Synonym ]:
Benzoic acid, 4-[[(4-carboxybutyl)[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]-
QCR-279
4-(((4-carboxybutyl)(2-((4-phenethylbenzyl)oxy)phenethyl)amino)methyl)benzoic acid
4-(((4-carboxybutyl)(2-(4-phenethylbenzyloxy)phenethyl)amino)methyl)benzoic acid
UNII-59K0Y58UAD
4-({(4-Carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid
Cinaciguat (JAN/INN)
BAY 58-2667
Cinaciguat

Biological Activity

[Description]:

Cinaciguat is an activator of guanylate cyclase (sGC), and used for acute decompensated heart failure.

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> Guanylate Cyclase

Research Areas >> Cardiovascular Disease

[In Vitro]

Cinaciguat (10 μM) significantly enhances intracellular cGMP generation. Cinaciguat does not dose-dependent effects on cell contraction and calcium transients[2].

[In Vivo]

Cinaciguat (10 mg/kg/day, p.o.) treatment in diabetic rats does not influence blood glucose levels, but leads to attenuated water intake. Cinaciguat treatment alleviates diabetes mellitus related oxidative stress, protects against DM related alteration of the NO-sGC-cGMP-PKG signalling, and alleviates DM related myocardium hypertrophy and apoptosis[1]. Cinaciguat (1-10-100 nM) induces concentration-dependent relaxations in strips from both WT and apo-sGC mice, but does not have any effect on phasic activity induced by PGF2α in WT or apo-sGC strips[3].

[Animal admin]

After confirmation of DM, rats are randomised into four groups: vehicle-treated control, cinaciguat-treated control, vehicle-treated diabetic and cinaciguat-treated diabetic groups. Animals are treated for 8 weeks with 0.5% methylcellulose vehicle or with the sGC activator cinaciguat in suspension p.o. (10 mg/kg/day), starting immeadiately after DM confirmation. Water bottles are filled every morning with the same amount of fresh tap water and daily water intake is measured. Animal cages are handled with care and are not moved after water bottle replacement to prevent spilling of water from the bottles. Body weight of the animals are recorded every 2 days and the dose of cinaciguat is adjusted accordingly.

[References]

[1]. Mátyás C, et al. The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus. Cardiovasc Diabetol. 2015 Oct 31;14:145.

[2]. Reinke Y, et al. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats. Format: AbstractSend to Eur J Pharmaco

[3]. Cosyns SM, et al. Influence of cinaciguat on gastrointestinal motility in apo-sGC mice. Neurogastroenterol Motil. 2014 Nov;26(11):1573-85.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
731.0±60.0 °C at 760 mmHg

[ Molecular Formula ]:
C₃₆H₃₉NO₅

[ Molecular Weight ]:
565.699

[ Flash Point ]:
395.9±32.9 °C

[ Exact Mass ]:
565.282837

[ PSA ]:
87.07000

[ LogP ]:
8.14

[ Vapour Pressure ]:
0.0±2.5 mmHg at 25°C

[ Index of Refraction ]:
1.614

[ Storage condition ]:
2-8℃

Cinaciguat

Names

Biological Activity

Chemical & Physical Properties

Related Compounds